Immunosenescence in systemic and multi-organ aging: mechanisms, inter-organ crosstalk, and translational opportunities Authors: Zhi-Guo Wu, Qiang-Qiang Zhao, Sheng-Rong Lin, Jia-Ying Lei, Cheng-Jun Yang, Shu-Ning Sun, Zhong-Qi Yang, Shi-Hao Ni, Xing-Ling Chen, Lu Lu Published: 2026 ABSTRACT AbstractAging is increasingly viewed as an organism-wide process marked by systemic decline and multimorbidity. This Review frames immunosenescence as a context-dependent mediator, amplifier, or consequence of multi-organ dysfunction, integrating niche-centered mechanisms, bidirectional immune–organ interactions, innate–adaptive remodeling, immune–tissue axes, and multidimensional biomarkers. We also highlight current limitations, including context heterogeneity and unresolved causality, and discuss senolytic, senomorphic, and other therapeutic strategies with potential relevance and limitations for healthspan extension. Subject terms: Computational biology and bioinformatics, Immunology Introduction As global population aging accelerates, the burden of age-related diseases poses a significant challenge to the health of older adults1–3. These clinical challenges are increasingly recognized as manifestations of systemic, multi-organ aging rather than isolated dysfunctions of individual tissues2–5. Aging is increasingly viewed as an interconnected organism-wide process in which multiple organ systems undergo parallel functional decline while influencing one another through endocrine, metabolic, neural, vascular, and immune communication4,6. Clinically, this systemic deterioration is reflected by multimorbidity, a defining feature of aging populations characterized by the co-occurrence of multiple chronic diseases across distinct organ systems6,7. Within this systemic framework, immunosenescence has been implicated as an important contributor to multi-organ aging3,8,9. At the organismal level, immunosenescence is associated with structural alterations of immune organs and a broad decline in immune competence9,10. At the cellular level, it is characterized by progressive dysregulation of immune-cell composition, function, and the surrounding immune microenvironment5,10. Chronic, low-grade inflammation accompanying aging is associated with perturbations in immune cell homeostasis11,12, and can coincide with functional impairment and structural damage across multiple immune cell populations—features widely regarded as hallmarks of immunosenescence12,13. In parallel, age-associated thymic involution and hematopoietic remodeling can bias hematopoietic stem-cell differentiation toward the myeloid lineage, resulting in reduced lymphoid output and potentially compromising immune surveillance14–16. Importantly, age-related changes in innate and adaptive immune compartments do not occur in isolation16. Dysfunctional immune cells, together with other senescent cell populations, can remodel local immune microenvironments through inflammatory and metabolic signaling9,13,17–19. This altered niche, in turn, may favor the accumulation and propagation of cellular senescence in both immune and non-immune tissues18, potentially supporting feed-forward interactions that contribute to organismal aging18–20. Given the extensive interconnection among physiological systems, immune aging may therefore facilitate the dissemination of inflammatory cues, stress signals, and disease susceptibility across organ boundaries, thereby amplifying age-related comorbidities13,21. However, the relationship between immunosenescence and organ aging is unlikely to be uniformly causal or unidirectional11,22. Functional evidence from preclinical genetic models, transplantation experiments, and senescent-cell clearance studies supports causal or mechanistic roles for immune aging and senescent-cell burden in selected experimental contexts, including impaired tissue repair, altered tumor immune surveillance, and inflammatory tissue remodeling3,23,24. In humans, however, much of the available evidence remains observational, associative, cross-sectional, or dependent on specific tissue and disease contexts25,26. Aging organs may also reciprocally reshape immune niches through endocrine, metabolic, neural, microbial, vascular, and stromal feedback signals11,25,26. Therefore, rather than defining immunosenescence as a universal central driver of aging, we frame it as a context-dependent driver, amplifier, or consequence of tissue dysfunction, with causal direction likely varying across tissues, disease states, and stages of aging3,27,28. Distinguishing when immune aging initiates tissue decline, when it amplifies pre-existing pathology, and when it reflects downstream organ dysfunction remains an important priority for future longitudinal and interventional studies11,22,25. In light of these considerations, a comprehensive yet evidence-calibrated understanding of immunosenescence as a systemic process is needed. This Review synthesizes current knowledge on the cellular and molecular features of immune aging, examines how immunosenescence may contribute to or reflect multi-organ functional decline through inter-system communication, and summarizes emerging strategies for assessing and targeting immune aging. By integrating mechanistic insights with translational perspectives, we aim to provide a conceptual framework for understanding immunosenescence-associated multi-organ aging and for guiding the development of more precise, context-sensitive intervention strategies. Mechanistic foundations of immunosenescence in systemic aging Age-associated immune dysfunction can be viewed as a systems-level process emerging from the interplay between tissue remodeling and immune-cell vulnerability29. Rather than arising from a single molecular lesion, immunosenescence reflects the progressive convergence of genomic instability, chronic inflammatory signaling, metabolic imbalance, and structural tissue alterations that may collectively reshape immune-cell differentiation, trafficking, and effector programs8,10. Importantly, these processes extend beyond the immune compartment and may influence tissue homeostasis and organ function in a context-dependent manner. Mechanistically, immunosenescence can be interpreted through a niche-centered framework13. In this Review, we define the niche-centered framework as a tissue-contextual model in which immunosenescence is shaped not only by cell-intrinsic immune defects but also by reciprocal interactions among immune cells, stromal cells, endothelial cells, extracellular matrix (ECM), metabolites, inflammatory mediators, and local biophysical cues25,30. In this context, inflammaging refers to the chronic, low-grade, sterile inflammatory state that develops during aging and is associated with senescent-cell secretory programs, damage-associated molecular patterns (DAMPs), altered innate immune sensing, and myeloid-skewed hematopoiesis11,31,32. This framework extends the concept of inflammaging by considering how inflammatory tone is generated, spatially maintained, and propagated within tissue microenvironments, while also linking immunosenescence with established pillars of aging, including genomic instability, mitochondrial dysfunction, cellular senescence, altered intercellular communication, stem-cell exhaustion, and ECM remodeling6,28,33. Immunometabolism provides a central, context-dependent mechanistic axis through which aging-associated mitochondrial dysfunction, nutrient-sensing imbalance, redox stress, and metabolite remodeling may reshape immune-cell fate, inflammatory tone, and tissue-level responses across organ systems22. Systemic aging entails persistent inflammatory cues, metabolic-redox dysregulation, and extracellular/vascular remodeling across organs6. These changes may interact in a feed-forward and mutually reinforcing manner: genomic and epigenomic instability can provide upstream inflammatory inputs, chronic inflammation and metabolic dysfunction can amplify oxidative and proteostatic stress11,18; and structural remodeling may progressively constrain immune-cell positioning and functional plasticity17. Together, these convergent processes may generate tissue microenvironments that favor the persistence and propagation of senescent immune states, providing the contextual basis for immune dysfunction and its potential systemic consequences (Fig. 1). The niche-centered framework of immunosenescence and its systemic modulators. It summarizes how epigenetic erosion, inflammatory amplification, metabolic reprogramming, and aging-related tissue remodeling converge to form a senescence-permissive immune niche associated with chronic sterile inflammation, impaired immune surveillance, and immune-cell dysfunction. Original figure prepared by the authors. Genomic and epigenomic instability as potential upstream inflammatory inputs Genomic instability is a conserved hallmark of aging and may provide one plausible upstream route to immune-cell senescence19. In proliferative immune compartments, repeated divisions are accompanied by telomere attrition, and critically short telomeres can trigger a DNA damage response culminating in stable cell-cycle arrest34,35. In T cells, which may undergo extensive clonal expansion across the lifespan, telomere shortening has been associated with reduced proliferative capacity and impaired responses to antigenic challenge36. Beyond telomere dynamics, immune aging is increasingly linked to epigenetic remodeling across the hematopoietic hierarchy37–39. Age-associated clonal hematopoiesis, often driven by mutations in epigenetic regulators such as TET2 or DNMT3A40, can bias hematopoietic output toward the myeloid lineage and is associated with a heightened inflammatory set-point in downstream progeny41–43. At the level of differentiated lymphocytes, senescent or exhausted T-cell states are accompanied by stable chromatin and enhancer configurations44, characterized by reduced accessibility at loci supporting self-renewal and sustained accessibility at exhaustion-associated regulatory regions, which may limit responsiveness to stimulation. A third, conceptually related mechanism involves the erosion of heterochromatin integrity and genome-wide hypomethylation during aging45, which can derepress retrotransposons and increase cytosolic nucleic acid accumulation46,47. These nucleic-acid intermediates may activate innate sensing pathways such as cGAS-STING48, promoting inflammatory transcriptional programs and the senescence-associated secretory phenotype (SASP), a secretome enriched in inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes, and thereby contribute to inflammaging in specific cellular and tissue contexts49–51. Inflammatory amplification and sterile inflammatory circuits A defining feature of immunosenescence is the emergence of persistent, sterile inflammation associated with senescent cells and their secretory programs40,52–54. Senescent cells produce SASP which can disrupt tissue architecture and alter immune-cell positioning55,56. Pro-inflammatory SASP components such as interleukin-6 (IL-6) and tumor necrosis factor (TNF) reinforce cell-autonomous senescence and can propagate senescent states to neighboring cells through paracrine signaling, thereby amplifying local and systemic inflammatory tone22,57,58. Sustained SASP signaling contributes to a state of chronic, low-grade, sterile inflammation characteristic of aging tissues12. At the signaling level, SASP-associated stimuli promote sustained activation of NF-κB58, enhancing pro-inflammatory cytokine production while concurrently suppressing autophagic pathways required for the clearance of damaged macromolecules59. The resulting accumulation of DAMPs, endogenous danger signals released from stressed or damaged cells, can provide continuous input to innate immune sensors, including the inflammasome60, further reinforcing inflammatory output and tissue stress61. Recent evidence has highlighted cytosolic nucleic acid sensing as an additional upstream contributor to sterile inflammation during aging62. In senescent cells, compromised nuclear envelope integrity and mitochondrial dysfunction can lead to the cytosolic accumulation of nuclear and mitochondrial DNA63. These nucleic acids engage the cGAS-STING pathway. In the context of immunosenescence, STING signaling may deviate from its canonical antiviral program64–66. Impaired vitamin D receptor signaling has been implicated in defective STING trafficking, biasing downstream responses toward NF-κB-driven inflammatory transcription while attenuating type I interferon (IFN-I) induction. This altered signaling configuration has been proposed to contribute to the coexistence of chronic inflammation and impaired antiviral defense observed in aged immune systems. Persistent activation of these pathways may, in turn, maintain NLRP3 inflammasome activity and sustained interleukin-1β (IL-1β) release, thereby potentially exacerbating tissue injury and inflammatory burden67. Immunometabolism as a central axis linking immune aging and tissue dysfunction Aging-associated niche remodeling can impose metabolic constraints on immune cells, reshaping their bioenergetic and biosynthetic programs68. In multiple immune lineages, aging is accompanied by a shift from oxidative phosphorylation (OXPHOS), the mitochondrial process that generates ATP through the electron transport chain (ETC)69, toward increased reliance on glycolysis70. Although glycolysis enables rapid ATP generation, this metabolic configuration is energetically inefficient and leads to the accumulation of lactate, which may further perturb the tissue microenvironment and immune-cell function71,72. Mitochondrial dysfunction represents a major contributor to this metabolic imbalance73. Defects in the ETC activity compromise OXPHOS efficiency and limit ATP availability, while reduced mitochondrial biogenesis impairs one-carbon metabolism, thereby constraining nucleotide synthesis and epigenetic maintenance74,75. As mitochondrial quality control deteriorates with age, ATP-dependent proteostatic mechanisms, including Lon protease-mediated degradation of oxidized proteins, become less effective76. This decline promotes the accumulation of ROS, which not only damages cellular macromolecules but also act as signaling intermediates that reinforce inflammatory and senescent states77. Excessive ROS accumulation induces oxidative stress, suppresses proteasomal activity, and increases protein oxidation, collectively predisposing cells to senescence and inflammaging78. Moreover, ROS-mediated modification of redox-sensitive kinases can activate NF-κB and p38 MAPK signaling, linking mitochondrial dysfunction to sustained DNA damage responses and inflammatory transcriptional programs79. Beyond protein damage, elevated ROS levels drive lipid peroxidation, generating oxidized phospholipid structures that can engage pattern-recognition receptors such as Toll-like receptors (TLRs) on myeloid cells, and may amplify inflammatory signaling80. In parallel, impaired lipid detoxification, associated with reduced activity of glutathione peroxidase 4 (GPX4), renders specific immune subsets, notably CD8⁺ T cells, susceptible to ferroptosis81,82, whereas regulatory T cells (Tregs) exhibit relative resistance. This differential vulnerability can skew immune-cell composition toward immunosuppressive phenotypes83,84. Metabolic dysregulation in the aging niche further extends to amino acid metabolism. Upregulation of indoleamine 2,3-dioxygenase (IDO) promotes tryptophan catabolism into kynurenine85, leading to local tryptophan depletion and activation of the GCN2 stress-response pathway in T cells, which can constrain immune activation86. Concurrently, kynurenine-mediated activation of the aryl hydrocarbon receptor (AhR) biases naïve T-cell differentiation toward regulatory lineages, supporting immunosuppressive circuits within aging tissues. Together, these metabolic alterations position immunometabolism as a central axis linking immune-cell senescence, inflammatory amplification, tissue-niche remodeling, and organ-level dysfunction. Biophysical constraints associated with tissue stiffness, fibrosis, and hypoxia Beyond biochemical and metabolic cues, the biophysical properties of aging tissues can constrain immune-cell behavior87. The ECM is a dynamic, tissue-specific network of non-cellular macromolecules, including collagens, elastin, fibronectin, laminins, proteoglycans, and glycosaminoglycans, that provides structural support as well as biochemical and biomechanical cues88. Age-associated ECM remodeling can contribute to fibrotic matrix accumulation, increased collagen cross-linking, and progressive tissue stiffening89. These changes generate mechanical signals that are sensed by infiltrating immune cells, leading to activation of YAP/TAZ-dependent mechanotransduction pathways. YAP/TAZ signaling can bias immune cells toward pro-fibrotic and pro-inflammatory programs, thereby reinforcing local tissue remodeling and establishing feed-forward interactions between fibrosis and inflammation90. In parallel, aging is frequently accompanied by microvascular rarefaction, defined as the loss, regression, or functional pruning of capillaries and other small vessels. By reducing tissue perfusion and oxygen delivery, microvascular rarefaction can generate hypoxic niches that reshape local immunometabolism and inflammatory responses91,92. Stabilization of hypoxia-inducible factor 1α (HIF-1α) under these conditions promotes glycolytic metabolism and can upregulate immune checkpoint molecules such as PD-L1 on myeloid cells, attenuating T-cell effector function93. Hypoxia-associated metabolic reprogramming also facilitates lactate accumulation and extracellular acidification, which impair natural killer (NK) cell cytotoxicity and reduce T-cell motility, collectively constraining immune surveillance in specific aging or diseased tissue contexts94. Spatial organization and propagation of senescent immune states The cumulative effects of inflammatory, metabolic, and biophysical niche remodeling are ultimately reflected in the spatial reorganization of immune responses within tissues. In aging tissues, tertiary lymphoid structures (TLSs) are increasingly recognized as ectopic, organized lymphoid aggregates that arise in chronically inflamed non-lymphoid organs95. These structures can contain variable combinations of B-cell follicles, T-cell zones, follicular dendritic-cell networks, plasma cells, and high-endothelial-venule-like vessels, thereby functioning as local immune niches outside canonical lymphoid organs96. In aging or age-associated disease contexts, TLSs may sustain antigen presentation, B-cell activation, and autoantibody production, linking persistent tissue damage with fibrosis and progressive organ dysfunction in selected settings97. Advances in spatial transcriptomics and imaging have further revealed that senescence can be influenced by local cellular neighborhoods98. Senescent immune cells can transmit pro-senescent signaling to adjacent stromal and parenchymal cells, generating spatially clustered zones of dysfunction. This neighborhood-dependent propagation highlights how immune aging extends beyond individual cells to shape tissue-level architectures of senescence, providing a spatial framework through which local immune dysfunction may become linked to multi-organ aging98,99. However, evidence for these spatial propagation models remains uneven across tissues, and their causal contribution to human multi-organ aging requires further validation through longitudinal, tissue-resolved, and perturbation-based studies100,101. Cellular hallmarks of immune aging While niche-level remodeling provides the tissue context, immunosenescence is reflected in lineage-specific cellular remodeling25. Across lineages, chronic exposure to inflammatory and metabolic stressors is associated with phenotypic changes in which core immune functions are selectively weakened, uncoupled from homeostatic constraints, or redirected toward persistent inflammatory states8. These cellular changes can be broadly organized into two asymmetric trajectories: innate constituents acquire a paradoxical phenotype of heightened basal activation, reduced stimulus discrimination or resolution capacity, and impaired pathogen clearance, thereby favoring exaggerated inflammatory output and less effective host defense15,102. Conversely, the adaptive arm exhibits numerical contraction and reduced functional fidelity, driven by replicative exhaustion and stable epigenetic reprogramming16. Collectively, these shifts can move the immune system away from coordinated protection toward a state characterized by reduced response fidelity, impaired immune surveillance, and increased inflammatory bystander effects (Fig. 2). Cellular and molecular features associated with the remodeling of innate and adaptive immunosenescence. It summarizes lineage-specific immune-aging changes in neutrophils, monocytes/macrophages, dendritic cells, NK cells, B cells, and T cells, highlighting reduced immune precision, impaired pathogen clearance, chronic sterile inflammation, tissue damage, and increased autoimmunity. Original figure prepared by the authors. Paradoxical activation and loss of effector precision in innate immune cells As primary responders to tissue stress and infection, innate immune cells frequently display prominent age-associated functional changes. Crucially, innate immune aging is not defined by global hypo-responsiveness, but by a paradox of heightened basal activation alongside impaired context-specific effector functions. This phenotype reflects quantitative and qualitative alterations across key lineages, including neutrophils, monocytes/macrophages, dendritic cells, and NK cells. Neutrophils Neutrophils play a central role in rapid antimicrobial defense, and their functional integrity is critical for early immune containment. In aging, however, neutrophils exhibit pronounced defects in directional migration, receptor expression, and microbicidal capacity103. Aged neutrophils have been reported to show impaired chemotaxis together with altered chemokine receptor profiles, such as reduced CXCR2 and increased CXCR4, consistent with perturbed trafficking and retention dynamics104,105. Age-associated alterations in gut microbiota composition may further contribute to neutrophil dysfunction by increasing exposure to microbial products that activate pathways such as TLR4-MyD88 signaling106. This signaling cascade promotes aberrant activation of the integrin CD11b/CD18 (Mac-1), facilitating the formation of neutrophil-platelet aggregates that hinder efficient transendothelial migration107. At the intracellular level, dysregulated phosphoinositide 3-kinase (PI3K) signaling leads to diffuse membrane distribution of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby reducing spatial signal fidelity required for accurate gradient sensing and directed motility108. In parallel, aged neutrophils exhibit preserved expression of pattern-recognition receptors such as TLR2 and TLR4, yet show reduced assembly efficiency of the NADPH oxidase complex (NOX2), resulting in attenuated respiratory burst activity and impaired formation of neutrophil extracellular traps (NETs)109. Defective clearance of senescent neutrophils further amplifies tissue damage in inflammatory or aging contexts. Excessive secretion of CXCL1 by senescent mast cells desensitizes CXCR2 signaling, promoting reverse transendothelial migration and systemic dissemination of activated neutrophils, suggesting a potential route through which local immune aging may influence distant inflammatory injury110. Monocytes and macrophages Age-associated neutrophil changes coexist with broader remodeling of the monocyte-macrophage axis, a system essential for tissue homeostasis, debris clearance, and resolution of inflammation. Aging hematopoietic stem cells (HSCs) exhibit a bias toward myeloid differentiation, increasing macrophage output but not functional competence111. Somatic mutations frequently acquired in aging HSCs, particularly in epigenetic regulators such as TET2 and DNMT3A, generate clonal macrophage populations with hyperactive NLRP3 inflammasome signaling40,60. These macrophage-lineage cells are reported to secrete elevated levels of IL-1 and IL-6, supporting a persistent inflammatory milieu even in the absence of infection112. Metabolic rewiring further compromises macrophage function. Upregulation of prostaglandin E2 (PGE2) signaling promotes glucose sequestration into glycogen stores, suppressing mitochondrial respiration and precipitating bioenergetic insufficiency that favors maladaptive inflammatory programs113,114. Concurrently, the decline in efferocytosis across aging tissues has been linked to impaired expression or signaling of receptors such as MerTK, leading to secondary necrosis of apoptotic cells and failure of inflammatory resolution115. Macrophage aging is also highly tissue-specific. Long-lived tissue-resident macrophages (TLF⁺) decline in number and function in select organs, whereas CCR2⁺ monocyte-derived macrophages are disproportionately affected by reduced monocyte output and quality. Declines in MHC-II⁺ macrophages further disrupt immune activation thresholds, contributing to inflammaging at the tissue level116. Dendritic cells Dendritic cells (DCs) occupy an important position at the interface of innate and adaptive immunity, and age-associated DC changes can have broad consequences for immune coordination117. In aged tissues, conventional DCs (cDCs) exhibit reduced expression of genes involved in cytoskeletal remodeling and migration, including CCR7, impairing their ability to traffic from peripheral tissues to lymph nodes even after antigen acquisition118,119. Similar to macrophages, DCs undergo PGE2-driven metabolic reprogramming that limits energy availability for antigen processing and presentation120. A compensatory mechanism involves cDC-derived type III interferons (IFN-III), which can counteract PGE2-mediated suppression and partially restore plasmacytoid DC (pDC) function121. However, this compensatory axis appears to be weakened during aging by a decline in pDC numbers and a marked reduction in IFN-I production. The resulting deficit in IFN-α/β signaling delays T-cell expansion and impairs B-cell class switching, contributing to weakened adaptive responses122. Notably, this interferon deficiency exhibits sex-specific differences, with more pronounced impairment observed in males123. NK cells NK cells are a major cytotoxic arm of innate immunity against senescent, transformed, and virus-infected cells124. Aging is associated with reduced NK-cell cytotoxic competence, with epigenetic dysregulation representing one contributing mechanism. Expression of the key transcription factors T-bet and EOMES declines with age, impairing NK cell maturation and, in some cases, inducing functional dedifferentiation125. This transcriptional instability is linked to reduced levels of miR-181a-5p, leading to derepression of inhibitory regulators such as NLK and BCL2 and further constraining NK cell development126. Extrinsic inhibitory signals compound these intrinsic defects. Senescent cells upregulate ligands such as HLA-E and ganglioside GD3, which engage inhibitory receptors on NK cells and suppress perforin-mediated cytotoxicity, enabling immune evasion127,128. These observations have informed therapeutic interest in NK inhibitory receptors, with monoclonal antibodies targeting NK inhibitory receptors under investigation as immune checkpoint interventions aimed at restoring senescent cell clearance129,130. Adaptive immune aging: contraction, exhaustion, and loss of precision In contrast to the innate immune system, where aging is frequently accompanied by elevated basal activation, adaptive immune aging is commonly characterized by progressive attrition, narrowing of functional diversity, and declining response fidelity. These changes reflect cumulative defects operating across the lifespan, beginning at the level of lymphoid organ architecture and extending to stable alterations in differentiation trajectories and effector programming of peripheral lymphocytes. Together, they erode the capacity of adaptive immunity to mount precise, durable, and context-appropriate responses to novel antigens. Thymic involution and loss of naïve T-cell supply A major developmental component of adaptive immune aging arises from thymic involution. The thymus undergoes profound and largely irreversible involution with age, leading to a sustained reduction in naïve T-cell output131. This process is driven in part by the numerical and structural decline of thymic epithelial cells, which depend on the transcription factor FOXN1 for differentiation and maintenance132. Age-associated downregulation of FOXN1 compromises thymic architecture and sharply limits thymopoiesis, resulting in a diminished influx of naïve T cells into the peripheral pool133. As thymic output wanes, maintenance of the naïve T-cell compartment increasingly relies on homeostatic proliferation, a process that is itself constrained by mitochondrial dysfunction and impaired autophagy in aging cells. This shift favors survival and expansion of memory T cells at the expense of naïve populations, leading to progressive contraction of T-cell receptor (TCR) diversity and reduced coverage of antigenic space134. Concomitantly, aging disrupts lineage balance within the T-cell compartment, often manifesting as inversion of the CD4⁺/CD8⁺ ratio. Expansion of CD8⁺ T cells occurs in the absence of adequate CD4⁺ helper support, resulting in quantitative preservation but qualitative decline of cellular immunity, a phenotype associated with increased susceptibility to infection and age-related pathology135,136. Replicative senescence and exhaustion of T cells With replenishment of naïve T cells curtailed, adaptive immune surveillance becomes increasingly dependent on pre-existing T-cell clones. Chronic compensatory proliferation and sustained antigenic exposure favor the emergence of replicative senescence and functional exhaustion137. At the cellular level, senescent T cells exhibit persistent metabolic stress and DNA damage, leading to activation of AMPK. AMPK-dependent recruitment of TAB1 promotes autophosphorylation and sustained activation of p38 MAPK, initiating a signaling program that suppresses expression of co-stimulatory molecules such as CD27 and CD28 and renders T cells refractory to antigenic stimulation138. Importantly, senescent T cells do not become inert. Instead, they retain the capacity to produce pro-inflammatory mediators while losing proliferative competence and antigen-specific responsiveness139. Cell-cycle arrest is maintained through activation of the p53-p21 axis and accumulation of p16, stabilizing the senescent state140. Concurrently, chronic p38 MAPK signaling suppresses autophagy, preventing the clearance of dysfunctional mitochondria and promoting the accumulation of ROS, which further reinforces inflammatory transcriptional programs and SASP72. T-cell exhaustion represents a closely related but distinct adaptive response to chronic antigenic stimulation. Exhausted T cells are characterized by sustained expression of multiple inhibitory receptors, including PD-1 and LAG-3, and by hierarchical loss of effector functions141. Crucially, exhaustion is generally more persistent than transient functional adaptation and is supported by stable epigenetic remodeling142. Exhausted T cells acquire distinct chromatin accessibility landscapes and exhaustion-specific enhancer architectures, particularly at loci encoding inhibitory receptors, rendering the exhausted state resistant to reversal even after antigen withdrawal143. In aging organisms, exhaustion and senescence frequently coexist, collectively constraining adaptive immune plasticity. Humoral immune aging and pro-inflammatory reprogramming of B cells Parallel to the decline in T-cell-mediated immunity, humoral defenses undergo marked functional deterioration. Aging B cells exhibit impaired capacity to generate high-affinity, class-switched antibodies, reflecting defects in the molecular machinery underlying antibody diversification144. Reduced stability of mRNA encoding the transcription factor E47 limits transcriptional activation of activation-induced cytidine deaminase (AID), an enzyme essential for class switch recombination and somatic hypermutation145,146. As a result, aged B cells remain biased toward low-affinity IgM production, and antibody responses elicited in older individuals are quantitatively preserved but qualitatively compromised147. Beyond loss of protective function, B cells can adopt more pro-inflammatory phenotypes with age. DAMP-rich inflammatory environments have been associated with the expansion or differentiation of age-associated B cell (ABC)-like populations60. These cells exhibit diminished antigen-specific responsiveness while persistently secreting inflammatory cytokines and autoantibodies, positioning them as active contributors to systemic inflammaging148. B-cell-derived plasma cells have also been implicated in tissue aging by accumulating in peripheral organs and producing excessive immunoglobulin G (IgG). Engagement of IgG with neonatal Fc receptors (FcRn) on stromal cells induces secondary senescence and SASP secretion, providing a plausible route through which humoral immune dysregulation could become connected to tissue-level senescence100. From immune-cell senescence to organ pathology: soluble, vesicular, and cellular routes of propagation Although the preceding sections describe lineage-specific features of immune aging, organ-level pathology is unlikely to arise from isolated cellular defects alone. Rather, senescent or chronically activated immune cells may influence tissue function through several partially overlapping local and circulating routes, including soluble inflammatory mediators, nucleic-acid danger signals, extracellular vesicles, and altered immune-cell trafficking or persistence. These routes provide a mechanistic bridge between cellular immunosenescence and the organ-specific alterations discussed below, while also emphasizing that the strength and directionality of these relationships vary across tissues, disease states, and stages of aging. A major route involves soluble mediators released by senescent or dysfunctional immune cells. The SASP, a secretome enriched in inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes, can reshape local tissue niches and amplify inflammatory signaling in adjacent stromal, endothelial, epithelial, and parenchymal cells53–56,59. SASP-associated cytokines such as IL-6, TNF, and IL-1β may sustain low-grade inflammatory tone, promote endothelial activation, and impair barrier integrity, whereas TGF-β and matrix-remodeling enzymes may favor fibroblast activation, ECM remodeling, and fibrotic repair programs in selected tissue contexts11,60,149–151. Chemokine axes, including CXCL9-CXCR3 and related inflammatory recruitment pathways, may further support the accumulation of immune cells in aging tissues and link systemic inflammaging with vascular and tissue-level dysfunction152. Importantly, these mediators should not be interpreted as uniformly pathogenic or universally causal; their effects depend on concentration, cellular source, tissue context, and whether the response is transient and reparative or persistent and maladaptive53,54,56. A second route involves nucleic-acid and mitochondrial danger signals. Aging-associated mitochondrial dysfunction, nuclear envelope instability, impaired autophagy, and retrotransposon activation can increase cytosolic or extracellular nucleic-acid species, including mitochondrial DNA (mtDNA), nuclear DNA fragments, and retrotransposon-derived nucleic acids18,45,48–50. In immune cells and tissue-resident cells, these DAMPs may activate innate sensing pathways such as cGAS-STING, NF-κB, and the NLRP3 inflammasome, thereby reinforcing sterile inflammatory circuits and promoting IL-1β-dominant inflammatory responses51,60–64,67. In some settings, altered cGAS-STING signaling may also contribute to an imbalance between inflammatory NF-κB activation and antiviral type I interferon responses, offering a plausible explanation for the coexistence of chronic inflammation and impaired pathogen defense in aged immune systems48,64–66. However, whether mtDNA release from senescent immune cells acts as an initiating cause, an amplifier, or a biomarker of tissue injury remains context-dependent and requires further longitudinal and interventional validation25,63,67. A third, less fully resolved route involves extracellular vesicles (EVs) and EV-associated microRNAs. Senescent, metabolically stressed, or chronically activated immune cells may release EVs carrying inflammatory proteins, lipids, mitochondrial components, nucleic acids, and microRNAs52,153,154. These vesicles can potentially transfer senescence-associated signals to endothelial, stromal, epithelial, and parenchymal cells, thereby extending immune-cell-derived stress signals beyond the immediate cellular neighborhood154,155. EV-associated microRNAs may also modulate gene-expression programs related to inflammation, mitochondrial metabolism, ECM remodeling, and cellular stress responses in recipient cells155–158. Because EV cargo composition varies by immune-cell lineage, tissue environment, and disease state, this route may help explain how localized immune-cell dysfunction becomes connected to broader systemic effects154,158. At present, however, the specific EV and microRNA signatures released by senescent immune-cell subsets remain incompletely defined, and their causal contribution to human multi-organ aging requires further study25,153,158. A fourth route involves redistribution, persistence, or impaired clearance of immune-cell populations themselves. Age-associated myeloid skewing can increase the production of inflammatory monocytes and macrophages, including clonal hematopoiesis-derived myeloid cells with heightened NLRP3 inflammasome activity39–43,60. Once recruited to tissues, these cells may produce IL-1β, IL-6, TNF, PGE2, and other mediators that impair resolution of inflammation, alter tissue repair, and favor fibrotic remodeling in the cardiovascular system, lung, kidney, and other organs113–116,159–162. Senescent or exhausted CD8⁺ T cells, including GZMK⁺ subsets, can retain inflammatory secretory capacity despite reduced proliferative or antigen-specific responsiveness, providing a route through which adaptive immune aging may contribute to endothelial activation, stromal remodeling, and tissue inflammation138–143,163,164. Age-associated B cells and plasma cells may further amplify systemic effects through inflammatory cytokines, autoantibodies, or IgG-mediated induction of secondary senescence in stromal cells100,144,148. Conversely, dysfunctional NK cells may contribute to tissue pathology less by producing inflammatory mediators than by failing to eliminate senescent, transformed, or stressed cells, thereby allowing senescent-cell burden and SASP production to persist125–127,129. Together, these soluble, vesicular, nucleic-acid-mediated, and cellular routes provide partially overlapping and context-dependent mechanisms through which molecular and cellular features of immunosenescence may become coupled to organ-specific pathology3,8,22,25,52,153. Their relative importance is likely to differ across organs. For example, skull marrow-derived myeloid cells and infiltrating CD8⁺ T cells may be especially relevant to neuroimmune aging, clonal hematopoiesis-derived inflammatory myeloid cells to cardiovascular and renal aging, alveolar macrophages and recruited monocytes to pulmonary injury, and barrier-derived microbial products to gut-immune-hematopoietic feedback loops159,161–167. Thus, the immune-organ axes discussed below should be viewed not as a fixed chronological sequence or a uniform causal hierarchy, but as context-dependent patterns of reciprocal immune-tissue communication22,25,26. To further clarify the cell populations most relevant to tissue dysfunction and whether their effects are primarily local, systemic, or both, representative immune-cell-mediator-organ relationships are summarized in Table 1. Table 1Immune-cell populations and mediators linking immunosenescence to organ-level pathologyImmune populationMain mediator/pathwayMain target tissue/cellLocal or systemic effectPotential pathological outcomeRepresentative referencesSenescent or exhausted CD8⁺ T cellsIFN-γ, GZMK, SASP-like inflammatory mediators, p38 MAPK-associated inflammatory programsCNS-resident cells, endothelial cells, fibroblasts, stromal cellsLocal after tissue infiltration; systemic when expanded in circulationNeuroinflammation, endothelial activation, stromal inflammation, fibrosis-like remodeling134,136,138GZMK⁺ CD8⁺ T cellsGZMK-associated inflammatory mediators; SASP-like secretory profileFibroblasts, endothelial cells, vascular wall cellsLocal and systemicVascular inflammation, fibrosis, tissue inflammatory remodeling163,164Inflammatory monocytes/macrophagesIL-1β, IL-6, TNF, NLRP3 inflammasome, PGE2, impaired efferocytosisEndothelium, vascular lesions, lung parenchyma, kidney tubules, CNS microenvironmentBoth systemic and localEndothelial dysfunction, delayed inflammatory resolution, fibrotic repair, tissue injury amplification60,113,115Clonal hematopoiesis-derived myeloid cellsTET2/DNMT3A-associated inflammatory programs; NLRP3 activation; IL-1/IL-6 secretionVascular wall, liver, kidney, lung, systemic circulationPrimarily systemic, with local tissue effects after recruitmentAtherosclerosis, vascular remodeling, chronic tissue inflammation, cardiorenal risk42,160,162NeutrophilsROS, NETs, altered CXCR2/CXCR4 trafficking, neutrophil-platelet aggregation, reverse transendothelial migrationEndothelium, lung, inflamed peripheral tissuesMainly local; may become systemic through recirculation or disseminationBarrier injury, microvascular inflammation, tissue damage during sterile or infectious inflammation103,110Dendritic cellsImpaired CCR7-dependent migration, reduced IFN-I, PGE2-associated metabolic suppressionLymph nodes, mucosal tissues, lung, adaptive immune compartmentsLocal and systemic through impaired immune coordinationWeak vaccine or antiviral responses, impaired T-cell priming, reduced B-cell class switching119,121,122Age-associated B cells / inflammatory B-cell populationsInflammatory cytokines, autoantibodies, altered antigen responsivenessSecondary lymphoid organs, inflamed tissues, systemic circulationPrimarily systemic, with local tissue deposition effectsAutoimmune-like inflammation, persistent inflammaging, impaired humoral precision144,148,253Plasma cells / IgG-producing B-lineage cellsIgG accumulation, FcRn-mediated stromal-cell signaling, secondary SASP inductionStromal cells, liver, spleen, peripheral tissuesSystemic with organ-specific deposition or signalingSecondary senescence, stromal inflammation, tissue aging signatures100Dysfunctional NK cellsReduced perforin-mediated cytotoxicity; impaired recognition or clearance of senescent and transformed cellsSenescent cells, tumor-prone tissues, infected cellsSystemic immune surveillance defectPersistence of senescent-cell burden, impaired tumor and viral surveillance, sustained SASP exposure125–127Senescent immune cells broadlySASP factors, EVs carrying inflammatory proteins, mtDNA, microRNAs, lipids, and DAMPsEndothelial, stromal, epithelial, and parenchymal cellsBoth local and systemicPotential propagation of senescence-associated signaling, inflammatory reprogramming, and ECM remodeling52,153,158Senescent immune cells and stressed tissue cellsmtDNA, nuclear DNA fragments, retrotransposon-derived nucleic acids, cGAS-STING, NF-κB, NLRP3Immune cells, stromal cells, endothelial cells, parenchymal cellsBoth local and systemicSterile inflammation, IL-1β release, impaired antiviral-inflammatory balance, tissue stress amplification48,64,67 Immune-cell populations and mediators linking immunosenescence to organ-level pathology Multi-organ aging landscapes shaped by reciprocal immune-tissue crosstalk Building on the soluble, vesicular, nucleic-acid-mediated, and cellular routes described above, organ-level manifestations of immunosenescence can be viewed as tissue-specific outcomes of shared immune-aging processes, including SASP-associated cytokines and chemokines, mitochondrial and nuclear nucleic-acid danger signals, EV-associated inflammatory or regulatory cargo, and the persistence or redistribution of senescent or dysfunctional immune-cell populations48,52,53,67. However, in most human aging contexts, causal mechanisms remain difficult to distinguish from associative changes, because immune remodeling and organ dysfunction often progress together and influence each other over time22,27. Accordingly, the contribution of these mechanisms likely varies across organs, disease states, and aging stages, and causal links between specific immune-aging features and organ-level decline remain to be fully established4,6,25. Multi-organ aging is increasingly viewed as a networked process shaped by endocrine, metabolic, neural, vascular, microbial, stromal, and immune communication4,26,28. Within this network, immunosenescence should be considered not only a decline in pathogen defense, but also a context-dependent mediator, amplifier, or consequence of tissue vulnerability3,8,25. Senescent immune states are associated with elevated basal inflammation, altered repair, weakened immune surveillance, and potential stress-signal propagation across organ boundaries10,11,21,153,157, whereas aging organs can reshape immune niches through metabolic, hormonal, microbial, neural, vascular, and stromal inputs25,26,31–33. Thus, the immune-organ axes discussed below are best understood as reciprocal, context-dependent interactions rather than fixed, linear, or strictly unidirectional causal pathways22,25–27. To capture these interactions, we discuss neuro-immune, cardio-immune, lung-immune, gut-immune, reproductive-immune, musculoskeletal-immune, kidney-immune, and endocrine-immune axes. These axes frequently converge on shared mediators, including chronic low-grade inflammation11,21,152, altered myeloid output31,42,160, immune checkpoint upregulation141,142, mitochondrial danger signaling64,67, EV-associated communication52,157, and SASP-associated tissue remodeling55,56,100. In this framework, immune aging may coordinate or amplify parallel degenerative trajectories across tissues, while also being shaped by feedback from aging organs themselves3,4,25. This framing emphasizes reciprocal association and context-dependent amplification, rather than implying that immunosenescence is a universally established primary cause of multi-organ aging22,26 (Fig. 3). Landscape of immunosenescence-mediated multi-organ dysfunction and aging-related pathologies. This schematic summarizes major immune–tissue axes linking immunosenescence with neuroinflammation, cardiovascular remodeling, gut–liver dysfunction, reproductive/endocrine decline, endocrine–metabolic dysregulation, respiratory injury, kidney damage, and musculoskeletal degeneration. Original figure prepared by the authors. Nervous system: erosion of immune privilege and maladaptive neuroinflammation during aging The nervous system has traditionally been regarded as an immune-privileged compartment; however, aging progressively weakens the anatomical and functional barriers that sustain this state168,169. Reduced blood-brain barrier integrity, altered meningeal lymphatic drainage, and age-associated microglial reprogramming can increase the interaction between peripheral inflammatory signals and central nervous system (CNS)-resident cells170. Several representative mechanisms connect immune aging with neuroinflammatory vulnerability. First, microscopic channels linking skull marrow to the meninges provide a context-dependent route through which neutrophils and monocytes can enter meningeal and cortical regions under pathological conditions165,171. In the setting of immunosenescence, these infiltrating myeloid cells can deliver pro-inflammatory mediators that exacerbate parenchymal injury and worsen neurological outcomes, including stroke-associated pathology166. Second, increased blood-brain barrier permeability allows greater entry of circulating CD8⁺ T cells into the CNS172. CXCR6-expressing CD8⁺ T cells have been reported to produce IFN-γ and contribute to inflammatory signaling associated with cognitive impairment173. Third, impaired VEGF-C-dependent meningeal lymphatic function reduces clearance of neurotoxic proteins such as amyloid-β and has been linked to microglial inflammatory activation and Alzheimer’s disease-related pathology174,175. Neuroimmune dysfunction is also closely linked to immunometabolic remodeling. Age-associated increases in prostaglandin E2 signaling through EP2 receptors on myeloid cells can suppress mitochondrial respiration and favor inflammatory activation states that are poorly supportive of neuronal integrity113,114. In parallel, lipid-droplet-accumulating microglia (LDAM) exhibit elevated oxidative stress and inflammatory mediator release, linking intrinsic microglial aging to impaired hippocampal neurogenesis and functional decline176. This neuroimmune relationship is bidirectional177. Blood-brain barrier disruption, impaired lymphatic drainage, neuronal injury, and chronic neuroinflammation can release danger signals and alter autonomic, endocrine, and hematopoietic regulation, thereby feeding back onto peripheral immune-cell function and systemic inflammatory tone178–180. Cardiovascular system: clonal hematopoiesis and inflammatory remodeling The cardiovascular system is continuously exposed to circulating immune cells and soluble inflammatory mediators, making vascular and cardiac tissues particularly sensitive to systemic immune remodeling181. Age-associated cardiovascular pathology can be influenced by upstream changes in the hematopoietic compartment, where immune-cell composition and inflammatory tone shift before or alongside overt vascular lesions159. One of the most extensively characterized mechanisms linking immune aging to cardiovascular disease is clonal hematopoiesis182. HSCs frequently acquire somatic mutations in epigenetic regulators such as TET2 and DNMT3A, generating mutant myeloid progeny with heightened NLRP3 inflammasome activity40,60,160. These cells produce increased levels of IL-1 and other inflammatory cytokines, a pattern associated with endothelial dysfunction, atherosclerotic progression, and elevated cardiovascular risk183–185. Endothelial-immune interactions provide a second major mechanism. In parallel, accumulation of GZMK⁺ CD8⁺ T cells and SASP-like inflammatory programs can activate fibroblasts and endothelial cells, supporting vascular inflammation and fibrosis149,163. Third, impaired macrophage efferocytosis contributes to unresolved vascular inflammation. Reduced ornithine decarboxylase (ODC)-dependent putrescine production limits continuous apoptotic-cell clearance, allowing debris and secondary necrosis to accumulate within vascular lesions, a pattern linked to plaque vulnerability186,187. Aging-associated cytokine exposure, including IFN-γ signaling, can induce endothelial CXCL9 expression, which recruits CXCR-expressing immune cells and sustains vascular wall inflammation152. Cardiovascular aging also feeds back onto immune function. Endothelial senescence, vascular stiffness, altered shear stress, plaque-derived mediators, and impaired tissue perfusion can recruit and reprogram circulating immune cells32,188. Thus, cardio-immune aging is best understood as a vascular-immune feedback loop rather than a one-way consequence of immunosenescence189,190. Respiratory system: dysregulated immune-cell recruitment and SASP amplification The aging lung faces persistent immunological pressure as the primary interface between the host and the external environment. Lifelong exposure to airborne pathogens and environmental insults places persistent demands on local immune surveillance, demands that become increasingly difficult to meet as immunosenescence progresses191,192. The aging lung can therefore be viewed as a convergence point where declining local antiviral immunity intersects with recruitment of systemically primed inflammatory myeloid cells191,193. Three mechanisms are particularly relevant. First, autoantibodies against type I interferons, including IFN-α and IFN-ω, increase in prevalence with age and can attenuate early antiviral signaling, contributing to vulnerability to severe respiratory viral infections194. Second, aging is associated with altered antigen-presenting and memory responses within the lung. Functional decline of dendritic cells, immune-checkpoint remodeling, and impaired lung-resident memory T-cell responses are linked to recurrent respiratory infection and pneumonia195. Third, alveolar macrophages undergo age-associated epigenetic and metabolic remodeling, including reduced accessibility at interferon-response gene promoters, which can limit interferon production upon pathogen encounter and worsen lung injury in susceptible contexts196,197. Importantly, pulmonary immune dysfunction is not solely dictated by local factors but is strongly shaped by systemic hematopoietic aging. Similar to the cardiovascular clonal-hematopoiesis pathway, TET2/ASXL1-mutant HSCs can generate inflammatory monocytes40. After lung recruitment, these monocytes can produce cytokines such as IL-6, disrupt the alveolar-capillary barrier, and increase susceptibility to severe inflammatory lung injury161. In parallel, senescent epithelial and stromal cells secrete SASP factors, including TGF-β, that support fibroblast activation and collagen deposition150,151,198. The lung-immune relationship is also reciprocal. Recurrent infection, barrier injury, hypoxia, environmental exposure, and fibrosis can reshape macrophage states and hematopoietic output, reinforcing immune aging rather than simply resulting from it199,200. Digestive system: microbiome dysbiosis and immune-gut-liver crosstalk The digestive system represents a complex internal ecosystem in which immune aging intersects with epithelial barrier integrity, resident microbiota, nutrient metabolism, and liver immune surveillance201. Immunosenescence is associated with altered gastrointestinal immune surveillance, microbial dysbiosis, increased barrier permeability, and immune-metabolic signaling changes that influence systemic inflammatory tone202. The first major axis involves the microbiome and mucosal immunity. Decline of bacterial taxa responsible for converting primary bile acids into secondary bile acids is associated with increased susceptibility to enteric infection and inflammatory colitis203,204. Reduced secretory IgA(SIgA) production can also permit fungal overgrowth and a shift toward pathobiont-like states, contributing to both local intestinal inflammation and systemic immune activation205. Immunosenescence further disrupts neuroimmune regulation of gastrointestinal function. Muscularis macrophages, which normally secrete bone morphogenetic protein 2 (BMP2) to support enteric nervous system activity and coordinated peristalsis, exhibit functional decline in aging tissues206. Their functional decline during aging is associated with gastrointestinal hypomotility, reduced nutrient absorption, malnutrition, and sarcopenia207. At the epithelial level, increased genomic instability in intestinal stem cells and reduced MHC-II expression can weaken immune surveillance and potentially increase susceptibility to malignant transformation208. Immune-metabolic crosstalk extends beyond the intestine to the liver. A similar CXCR6⁺ CD8⁺ T-cell pattern occurs in aged livers, where IL-15-linked accumulation is associated with hepatocellular injury and fibrotic remodeling209. Aging may also intersect with immune-evasion programs in digestive malignancies. In PDAC, autophagy-dependent reduction of surface MHC-I limits CD8⁺ T-cell recognition and promotes immune escape, although whether immunosenescence directly amplifies this process remains to be clarified210. Declining tight-junction integrity allows microbial products such as lipopolysaccharide (LPS) to enter the circulation. Circulating LPS can promote HSC myeloid bias and reinforce systemic inflammatory tone167. Gut microbial composition also influences distal immune environments, as young-associated microbiota can partially reverse microglial senescent phenotypes in murine models211. Thus, dysbiosis should not be interpreted only as a consequence of immune aging. It can also act as an upstream modifier of systemic immune and metabolic aging, supporting a bidirectional gut-immune-liver framework212,213. Reproductive system: inflammaging of the hypothalamic-pituitary-gonadal axis and reproductive decline Immunosenescence has been implicated in reproductive aging through combined central neuroendocrine disruption and local immune microenvironmental remodeling. Reproductive aging is shaped, in part, by chronic low-grade inflammation that affects the hypothalamic-pituitary-gonadal axis while also influencing follicular dynamics and tissue-level immune tolerance214. At the central level, inflammatory cytokines such as TNF-α and IL-1β can act on hypothalamic GnRH neurons, attenuating pulsatile GnRH secretion and suppressing downstream luteinizing hormone (LH) and follicle-stimulating hormone release215,216. This inflammatory interference contributes to impaired gonadal function and progressive reproductive decline during aging217. Local immune dysregulation further amplifies reproductive aging. In the aging ovary, stromal cells exhibit reduced collagenase activity alongside increased pro-inflammatory signaling, leading to excessive ECM deposition and fibrosis218. This fibrotic remodeling restricts follicular development and, through paracrine mediators such as IL-6, contributes to primordial follicle atresia, ovarian aging, and earlier onset of menopause219. In males, immunosenescence is associated with depletion of MRC1⁺ tissue-resident macrophages that normally sustain testicular immune privilege. Their loss, together with increased infiltration of pro-inflammatory monocytes and CD8⁺ T cells, has been linked to blood-testis barrier disruption and testicular atrophy220. At the level of germ-cell quality, age-associated NAD⁺ decline in oocytes and granulosa cells can impair mitochondrial ATP production, increase oxidative stress, and reduce oocyte competence221. In the uterus, transient senescence-like programs normally support implantation, but persistent SASP production in aging tissues is associated with impaired implantation and pregnancy loss222–224. Finally, reproductive aging intersects with tumor susceptibility. Accumulation of p53 mutations in aging ovarian and fallopian tube epithelia increases oncogenic potential, while concurrent immunosenescence drives tissue-resident T cells toward exhausted phenotypes225. Together, reduced immune surveillance and epithelial genomic instability may permit malignant-clone expansion, contributing to ovarian cancer risk in older women. The reproductive axis also shows reverse immune-organ regulation. Changes in sex hormones, gonadal steroids, tissue senescence, and endocrine feedback can reshape immune metabolism, inflammatory tone, and resident immune niches226. Reproductive aging and immunosenescence, therefore, likely influence each other227. Musculoskeletal system: bone marrow niche disruption, sarcopenia, and frailty associated with immunosenescence The musculoskeletal system lies at the intersection of structural support, movement, metabolism, and immune-cell production. Aging of immune niches within bone marrow and peripheral tissues is associated with catabolic signaling, impaired regeneration, and tissue remodeling that contribute to osteoporosis, sarcopenia, and frailty228. Bone marrow represents both the primary site of hematopoietic stem-cell differentiation and a critical locus of immune aging229. Age-associated loss of sympathetic adrenergic innervation disrupts regulatory inputs that normally constrain HSC fate decisions183. This shift favors myeloid bias, inflammatory monocyte expansion, osteoclast activity, and bone resorption, all associated with osteoporosis susceptibility230. Impaired immune regulation also compromises skeletal repair. Aging-associated reprogramming of skeletal stem cells suppresses osteogenic gene expression while enhancing inflammatory programs, creating a fracture-site environment in which bone resorption can outpace formation231,232. Muscle aging is similarly shaped by immune-tissue crosstalk. Muscle-resident macrophages normally support regeneration through secretion of PGE2, which activates EP4 signaling on muscle stem cells (MuSCs)233. In aging muscle, elevated expression of the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) reduces local PGE2 availability, impairing MuSC activation and exacerbating sarcopenia234. Systemic immune aging further contributes to muscle dysfunction through adipose-immune crosstalk. Pro-inflammatory B-cell populations in visceral adipose tissue can activate the NLRP3 inflammasome and elevate systemic inflammatory tone60,148. Similar to the vascular SASP-fibroblast axis, accumulating GZMK⁺ CD8⁺ T cells are associated with ECM remodeling, tissue stiffening, and arthritis164. In this setting, persistent inflammatory lymphocyte and myeloid activity may provide a cellular route through which systemic immune aging becomes coupled to local matrix remodeling, impaired repair, and declining musculoskeletal resilience164,232,235. The musculoskeletal system also feeds back onto immune aging. Bone loss, marrow adiposity, inactivity, and frailty alter hematopoietic niches, metabolism, and inflammatory mediator release104,232,235. These changes can bias immune-cell production and reduce immune resilience, linking physical decline with immunosenescence. Urinary system: renal inflammation, fibrosis, and immune-mediated kidney aging As the principal organ responsible for filtering systemic metabolic waste, the kidney is chronically exposed to circulating inflammatory mediators and metabolic byproducts236. During aging, this exposure is associated with a shift in renal immune responses from transiently reparative to more persistent inflammatory states, in which unresolved inflammation is linked to fibrotic remodeling and tubular bioenergetic stress237. Aging markedly increases susceptibility to the transition from acute kidney injury to chronic and irreversible renal dysfunction. This vulnerability has been linked, in part, to immunosenescence-associated alterations in the hematopoietic compartment. Myeloid cells derived from HSCs harboring age-acquired mutations such as TET2 display exaggerated inflammatory programs40. During injury, these cells show impaired clearance of necrotic debris while secreting IL-1, IL-6, and other cytokines, a pattern associated with delayed injury resolution and fibrotic repair162. Adaptive immune dysregulation further amplifies renal inflammation. T-cell exhaustion, impaired Treg function, and expansion of Th17-skewed responses have been implicated in glomerular barrier injury, proteinuria, and local inflammatory amplification238. At the epithelial-immune interface, persistent vascular cell adhesion molecule-1 (VCAM1) expression recruits T cells and macrophages, creating a pro-inflammatory, pro-fibrotic niche that impairs regeneration and contributes to renal fibrosis239,240. Metabolic competition adds another layer to kidney aging. Senescent tubular epithelial cells can rely on glutaminase-1 (GLS1)-dependent glutaminolysis to maintain intracellular pH, a survival adaptation associated with enhanced SASP production and neighboring tissue injury241–243. In parallel, accumulation of CD38⁺ macrophages can reduce NAD⁺ availability, depriving tubular epithelial cells of a key metabolic cofactor and contributing to bioenergetic insufficiency244. These renal examples link several routes described above—circulating inflammatory mediators, persistent myeloid-cell activity, SASP-associated tubular stress, and metabolic competition—to fibrotic remodeling and delayed injury resolution162,239. The kidney also illustrates reverse immune-organ feedback. Reduced filtration, uremic toxins, altered salt handling, hypoxia, and tubular stress can reshape immune-cell function and hematopoiesis245. Renal aging can therefore be interpreted as an immune-metabolic feedback loop rather than a one-way consequence of immunosenescence244,245. Endocrine system: metabolic-immune crosstalk and endocrine aging Endocrine signaling provides a central integrative framework for coordinating metabolic homeostasis across organ systems. During aging, immunosenescence intersects with endocrine regulation, linking neuroinflammation, glandular immune remodeling, and metabolic dysregulation in ways that can reinforce systemic aging phenotypes246,247. This interface also allows hormonal and metabolic signals to reshape immune fate, inflammatory tone, and immunometabolism Centrally, age-associated hypothalamic immune activation alters neuroimmune crosstalk critical for endocrine control248. In experimental models, immunosenescence-driven microglial activation has been shown to downregulate Menin, an epigenetic regulator required for maintenance of hypothalamic neuronal function249. Reduced Menin expression impairs D-serine synthesis, diminishes neuronal plasticity, and has been linked to systemic metabolic aging, bone loss, and cognitive decline250. Peripheral metabolic tissues are similarly shaped by immune-metabolic crosstalk. Adipose tissue contains lipid-associated macrophages (LAMs) that normally clear excess lipids via Trem2-dependent pathways. With aging and metabolic stress, LAM function becomes compromised, leading to lipid spillover, chronic inflammation, and propagation of insulin resistance251. Under immunosenescent conditions, β cells can enter a senescent state characterized by p16 expression and SASP secretion, attracting pro-inflammatory macrophages and becoming associated with progressive islet dysfunction and increased susceptibility to diabetes mellitus252. Humoral immune aging further intersects with endocrine decline. Expansion of age-associated B cells can predispose to plasma-cell differentiation and autoantibody production against endocrine tissues, including the thyroid and pancreatic islets. These autoimmune responses may contribute to glandular injury and functional deterioration, reinforcing the link between immune aging and endocrine dysfunction253. Across these central and peripheral endocrine sites, inflammatory cytokines, senescent β-cell SASP programs, macrophage recruitment, and autoantibody-producing B-lineage cells form converging immune-endocrine routes rather than a single linear pathway251,253. The endocrine system also mediates reverse regulation. Changes in insulin, glucocorticoids, thyroid hormones, sex steroids, adipokines, and hypothalamic signals can reshape immune metabolism and inflammatory set-points217. Therefore, endocrine aging should not be viewed only as an outcome of immunosenescence; it may also modulate the pace and phenotype of immune aging226. Decoding the biological clock via multidimensional quantification of immunosenescence and multi-organ aging Accurate estimation of biological age is increasingly recognized as an important component of risk stratification and intervention planning in age-related diseases. In studies of immune aging, assessment strategies have traditionally relied on a limited set of parameters, such as peripheral immune-cell composition (for example, inversion of the CD4/CD8 ratio) or circulating inflammatory mediators including IL-6 and TNF-α. Although these measures provide useful information, they capture only restricted aspects of immunosenescence and do not adequately reflect the marked heterogeneity of aging trajectories observed across individuals, tissues, and organ systems. Recent work, therefore, conceptualizes immunosenescence as a multidimensional biological state that cannot be resolved by single readouts. Instead, its quantification increasingly integrates information across epigenetic, transcriptional, proteomic, metabolic, spatial, and functional layers. Such composite frameworks improve estimation of immune biological age and provide mechanistic insight into how immune aging relates to coordinated functional decline across organs (Fig. 4). Integrated framework for quantifying immunosenescence and its clinical applications. This schematic summarizes how epigenetic, spatial transcriptomic, plasma proteomic, immune repertoire, and immune-function platforms can be integrated with characteristic indicators, environmental modulators, and clinical applications for assessing immune biological age and guiding intervention planning. Original figure prepared by the authors. Systemic clocks integrating epigenetics, proteomics, and immune architecture Early approaches to quantifying immune biological age have focused on DNA methylation-based clocks. Models such as the Hannum, Horvath, and PhenoAge clocks infer biological age from methylation patterns at defined CpG loci in peripheral blood and show consistent associations with mortality and age-related morbidity254. In immune cells, age-associated methylation drift correlates with chronic inflammatory tone and inflammaging phenotypes, supporting the use of epigenetic signatures as integrative markers of immune aging rather than proxies of chronological age alone255,256. Beyond bulk methylation signatures, single-cell epigenomic profiling has refined this picture. Single-cell ATAC-seq analyzes demonstrate that aged innate immune cells adopt an epigenetically primed state, characterized by increased chromatin accessibility at pro-inflammatory gene promoters257. This configuration does not necessarily cause constitutive cytokine production but predisposes cells to exaggerated responses upon secondary stimulation, capturing a latent dimension of immune aging that is invisible to steady-state cytokine measurements258. Complementary measurements of single-cell protein synthesis and metabolic flux further highlight immunometabolic imbalance, particularly shifts between glycolysis and oxidative phosphorylation, as a core feature of immune functional declinee259. Immune aging, however, is not solely encoded in molecular states but is embedded within tissue architecture. Spatial transcriptomic and imaging-based studies have introduced the concept of spatial aging clocks, in which the density, localization, and cellular neighborhood of immune infiltration modulate parenchymal cell senescence98,260. For example, T cells infiltrating the brain parenchyma exert pro-senescent effects on adjacent oligodendrocytes and pericytes, illustrating a neighborhood-dependent propagation of aging phenotypes98. In organs such as skin and liver, aging is associated with remodeling of fibroblast-macrophage communication networks, marked by co-localization of inflammatory pathways including TNF, CXCL, and MIF signaling, which may serve as spatial biomarkers of tissue-specific immunosenescence261. At the systemic level, plasma proteomic clocks have become widely adopted tools for assessing organ-specific biological age. High-throughput proteomic platforms quantify thousands of circulating proteins, allowing inference of aging trajectories for individual organs such as the heart, kidney, and brain262. These analyzes reveal network effects in organ aging; for instance, accelerated kidney aging often precedes and predicts cardiovascular decline, highlighting functional coupling within the cardiorenal axis6,263. Integrative frameworks now combine plasma proteomics with medical imaging and machine-learning models to improve the prediction of mortality and disease risk. A representative example is the inflammaging clock iAge, which outperforms single inflammatory markers such as CRP. Notably, the chemokine CXCL9 emerges as a core contributor to iAge, serving both as a quantitative marker of immune aging and a mechanistic link between inflammaging and endothelial dysfunction264. Together, these findings position systemic proteomic clocks as effective bridges between immune aging and multi-organ pathology. Because senescence-associated secretory programs mediate many downstream effects of immune aging, there is growing interest in refining senescence-specific molecular markers. Conventional SASP detection lacks specificity and can be confounded by acute inflammatory states. Recent work demonstrates that the CDKN2A locus encodes multiple transcripts, and that p16 variant 5 provides greater specificity for senescent cell burden than aggregate p16 expression. In senolytic trials, such as dasatinib plus quercetin, p16 variant 5 levels in T cells more accurately predicted improvements in bone metabolism than total p16 measurements265. In parallel, mass spectrometry-based top-down proteomics has identified specific HMGA2 proteoforms carrying distinct acetylation and phosphorylation patterns that are preferentially associated with senescent cells. These proteoforms offer high signal-to-noise candidates for non-invasive assessment of senescent cell burden in vivo266 . Cellular, repertoire, and functional metrics capturing senescence heterogeneity Despite advances in systemic clocks, immunosenescence cannot be captured by a single molecular layer. Its quantification requires integration of biomarkers reflecting upstream drivers, core cellular states, and downstream functional consequences. At the cellular level, replicative stress and DNA damage trigger the p53-p21 axis and p16-mediated cell-cycle arrest, establishing p16^INK4a expression in peripheral T cells as a robust molecular signature of immunosenescence134. This senescent state is further defined by lysosomal expansion and elevated SA-β-gal activity, a key quantitative indicator correlating with systemic inflammation and physiological decline267. Age-associated accumulation of GZMK+ T cells, defined by exhaustion markers and SASP signatures, drives inflammaging more precisely than the CD4/CD8 ratio. Concurrently, B-cell dysfunction precipitates aberrant IgG deposition in tissues like the liver and spleen, inducing secondary senescence and serving as a novel histological biomarker268. Mechanistic defects in T cells, particularly the loss of Mitochondrial Transcription Factor A (TFAM), drive mtDNA instability and respiratory chain failure, triggering cytokine storms that exacerbate immune aging269. Consequently, TFAM protein levels and cytoplasmic mtDNA leakage constitute core benchmarks for assessing immunometabolic senescence270. In microglia, intracellular lipid accumulation in LDAM provides a direct measure of functional failure271. Additionally, quantifying γ-H2AX foci at telomeric regions offers superior sensitivity for assessing genomic instability compared to telomere length alone272. Crucially, immunosenescence is reflected in the immune repertoire—characterized by contracted TCR/BCR diversity and clonal skewing—and functional capacity. Benchmarks such as vaccine responsiveness and cytokine dynamics calibrate molecular clocks with clinically actionable insights273. These functional measures capture the aging immune system’s capacity to mount coordinated responses, bridging mechanistic insights with translational perspectives. Beyond immune cells themselves, aging hallmarks extend to the extracellular and psychosocial environment274,275. Progressive stiffening and fibrosis of the ECM disrupt mitochondrial homeostasis, induce cellular senescence, and accelerate stem cell exhaustion, forming a self-reinforcing loop between tissue mechanics and immune aging274,276. Moreover, the positive correlation between plasma IL-23R levels and organismal aging suggests that IL-23R could serve as an extracellular senescence biomarker275. At the organismal level, psychosocial isolation, often overlooked in molecular frameworks, activates chronic neuroendocrine stress responses that intersect with immune regulation, thereby accelerating systemic aging trajectories274,277. Finally, immunosenescence exhibits pronounced sexual dimorphism. Females generally maintain higher CD4/CD8 ratios and more robust interferon production by plasmacytoid dendritic cells, partly due to dosage effects of X-linked immune genes such as TLR7. These differences shape distinct aging trajectories of immune subsets and necessitate the incorporation of biological sex as a critical variable in immune aging quantification278–280. Translational therapeutic strategies targeting immunosenescence and multi-organ aging Immunosenescence-associated tissue dysfunction involves heterogeneous cellular states that differ in their degree of irreversibility, pathological impact, and functional necessity for tissue maintenance. As a result, effective intervention strategies must be context dependent25,281. Stable senescent cell states associated with persistent SASP production, impaired repair, or tissue-damaging inflammatory programs represent rational targets for elimination, whereas immune cells that retain functional plasticity may benefit more from phenotypic modulation or metabolic reprogramming282,283. Accordingly, therapeutic strategies targeting immunosenescence can be organized into three mechanistic categories: interventions that directly eliminate or reprogram senescent immune cells; interventions that target non-immune senescent cells and indirectly remodel immune niches; and interventions that act on shared senescence-associated pathways across immune and non-immune compartments281,284. Pleiotropic small molecules and contextual interventions can then be positioned within this framework as immune-niche or immunometabolic modulators285. Target compartments and pathway classes in senotherapeutic interventions Pharmacological targeting of immunosenescence should distinguish target compartment, cell state, and pathway class284. Direct immune-cell targets include senescent or exhausted T cells, inflammatory macrophages, age-associated B cells, dysfunctional NK cells, CD38⁺ macrophages, and immune subsets with persistent checkpoint or SASP-like programs286,287. These cells can influence inflammatory tone, immune surveillance, and tissue repair, but their roles remain context dependent and not uniformly detrimental16,24. Non-immune senescent targets include endothelial cells, fibroblasts, epithelial cells, stromal cells, and parenchymal cells whose SASP can recruit, activate, or suppress immune populations within tissue niches53,56,288. Clearing or reprogramming these non-immune cells can reduce inflammatory niche pressure and indirectly improve immune-cell function288–290. Therefore, apparent “immune rejuvenation” after senotherapeutic treatment may reflect direct effects on immune cells, indirect remodeling of tissue niches, or both286,291. Another distinction concerns shared versus compartment-selective pathways286. Shared therapeutic pathways include BCL-2/BCL-xL, p53-p21, p16INK4a-associated programs, PI3K-AKT-mTOR, NF-κB, JAK/STAT, HSP90, glutaminase-1 (GLS1)-dependent metabolism, mitochondrial dysfunction, and immune-checkpoint signaling, although the relative dependence on these survival programs may differ among senescent or exhausted T cells, inflammatory macrophages, age-associated B cells, and dysfunctional NK cells281,282,284. These pathways operate across immune and non-immune compartments, creating opportunities for broad intervention but also increasing the risk of off-target toxicity, myelosuppression, or unintended immune suppression, particularly when cellular heterogeneity and tissue-specific immune functions are not adequately resolved281 (Table 2). Table 2Representative intervention strategies targeting immunosenescenceDrug nameCategoryMajor targetKey mechanism of actionTargeted senescence pathwayEvidence levelMajor target organ systemTranslational considerationsRef.SSK1Senolytic (Prodrug)SA-β-gal High Cells (Broad spectrum)Gemcitabine prodrug cleaved by lysosomal β-gal; activates p38 MAPK and MKK3/6 to induce apoptosis via mitochondrial DNA damageMetabolic/Enzymatic (Targeting high β-gal activity rather than SCAP directly)Preclinical (In vitro, Mouse)Musculoskeletal (Joints), Lung, LiverBroad-spectrum clearance, high specificity, extremely low systemic toxicity267Navitoclax (ABT-263)SenolyticBCL-2, BCL-xL, BCL-wBH3 mimetic; inhibits anti-apoptotic BCL-2 family proteins, triggering MOMP and apoptosisBCL-2 Family (Anti-apoptotic defense)Preclinical and Clinical TrialsHematopoietic System (HSCs), Bone, Muscle, LungDose-limiting thrombocytopenia and neutropenia294Venetoclax (ABT-199)SenolyticBCL-2 (Selective)Selective BCL-2 inhibition; spares BCL-xL to avoid platelet toxicityBCL-2 FamilyPreclinicalImmune System (Zebrafish inflammation), LiverSafer than Navitoclax but requires monitoring for TLS and neutropenia326Dasatinib + Quercetin (D + Q)Senolytic (Combination)Ephrins, Src Kinase (D) + PI3K, BCL-2 (Q)D: Inhibits Src/Ephrin dependence; Q: Inhibits PI3K/AKT and BCL-2 members; synergistic clearance of SnCsSCAP Network (Ephrins, PI3K, p53/p21, BCL-2)Clinical (Human Trials) and PreclinicalLung (IPF), Adipose, Bone, CardiovascularMyelosuppression, GI reactions; often uses intermittent dosing290FisetinSenolytic (Flavonoid)PI3K/AKT/mTOR, NF-κBReduces p16 expression; inhibits PI3K/AKT signaling; suppresses oxidative stress via NRF2/ATF4PI3K/AKT, SASP (IL-6, TGF-β)Preclinical and Clinical (Pilot)Systemic (Kidney, Adipose), ImmuneLow toxicity (dietary source); high doses may cause GI discomfort285RutinSenomorphicATM Kinase, HIF-1α, TRAF6Disrupts ATM-HIF1α and ATM-TRAF6 interactions; prevents ASAP to SASP transitionSASP Regulation (Dampens cytokine secretion)PreclinicalVascular (Endothelium), Tumor MicroenvironmentNatural phytochemical; enhances chemotherapy efficacy297FOXO4-DRISenolytic (Peptide)p53-FOXO4 InteractionPeptide antagonist; blocks FOXO4-p53 binding; releases p53 to induce mitochondrial apoptosis (intrinsic pathway)p53/p21 Axis (Nuclear sequestration of p53)PreclinicalKidney, Fur/Skin, ChondrocytesSignificant effects in progeroid models; needs to address peptide delivery and tissue specificity32717-DMAG (Alvespimycin)SenolyticHSP90HSP90 inhibition; destabilizes client proteins (AKT, p53, BCL-2); promotes proteasomal degradation; induces apoptosis.Proteostasis / HSP90 (Chaperone addiction)PreclinicalSystemic (Progeroid models), CancerClinical observations of peripheral neuropathy and renal dysfunction328Cardiac Glycosides (Ouabain, Digoxin)SenolyticNa+/K+ ATPaseInhibition of Na⁺/K⁺ pump; causes electrochemical imbalance; induces cellular acidification; upregulates NOXA expression; triggers apoptosis.BCL-2 Family (NOXA induction), Ion HomeostasisPreclinicalBroad Spectrum (Lung, Tumor)Narrow therapeutic window; risk of arrhythmias; requires strict monitoring of renal function302BPTES / CB-839Senolytic (Metabolic)Glutaminase 1 (GLS1)Inhibit glutaminolysis; prevents neutralization of lysosomal acidosis; lowers pH; induces senescence cell lethality.Metabolic Vulnerability (Glutamine addiction/pH regulation)PreclinicalKidney, Lung, MuscleImproves obesity-related diabetes and atherosclerosis; may slightly delay wound healing243uPAR-CAR T cellsImmunotherapy (Senolytic)uPAR (PLAUR) on SnCsCAR T-cells recognize surface uPAR; mediate perforin/granzyme-dependent lysis of senescent cellsImmune Clearance (Targeting surface antigen uPAR)PreclinicalLung, Liver, Intestine (Gut)Risk of Cytokine Release Syndrome (CRS); high cost; self-limiting329GPNMB VaccineImmunotherapy (Vaccine)GPNMB on Senescent EndotheliumPeptide vaccine; induces anti-GPNMB antibodies; clears GPNMB+ cells via ADCCImmune Clearance (Targeting surface antigen GPNMB)PreclinicalCardiovascular (Vascular Endothelium), AdiposeLong-acting potential compared to small molecules; improves metabolic parameters289RapamycinSenomorphic / ImmunomodulatormTORC1Inhibits mTOR; reduces translation of SASP factors (IL-1α); promotes autophagy; improves T-cell memorymTOR Signaling, SASP, AutophagyClinical and PreclinicalImmune System (T cells), SystemicRisk of immunosuppression (infection); hyperlipidemia; affects wound healing330,331MetforminImmunometabolic ModulatorAMPK, Mitochondria (Complex I)Activates AMPK; inhibits mTOR; shifts T-cell metabolism to OXPHOS; balances Th17/Treg ratioMetabolic Reprogramming, SASP, InflammagingClinical and PreclinicalImmune System (T cells), Liver, SystemicGI reactions; lactic acidosis (rare); Vitamin B12 deficiency risk283SpermidineImmunometabolic RejuvenatoreIF5A / TFEBHypusinates eIF5A; promotes translation of TFEB; induces Autophagy; restores B/T cell functionAutophagy, ProteostasisClinical and PreclinicalImmune System (B cells, T cells)Polyamine compound; high doses may cause GI discomfort332NAD+ Precursors (NR, NMN)Immunometabolic RejuvenatorSirtuins (SIRT1), MitochondriaRestores intracellular NAD+ pools; activates SIRT1; prevents T-cell exhaustion; enhances mitochondrial respirationMitochondrial Dysfunction, Sirtuin SignalingPreclinical and ClinicalImmune System (T cells), Heart, SystemicLow oral bioavailability; generally well-tolerated333MitoQ / SkQ1Antioxidant (Mitochondrial)Mitochondrial ROSAccumulates in mitochondria; neutralizes ROS; prevents oxidative damage to thymic stromaMitochondrial Dysfunction, Oxidative StressPreclinicalThymus, Skin, EyeRestores NO bioavailability; preserves vascular endothelial function334Tacrolimus (Low-Dose)ImmunomodulatorCalcineurin / NF-ATPartial inhibition of NF-AT; restores T-cell proliferation; reduces “inflammaging” cytokines (IFN-γ)T-cell Activation/SignalingPreclinical and ClinicalImmune System (T cells), Skin GraftsPK differences in elderly; requires dose adjustment (often half of young dose)306RuxolitinibSenomorphic (JAK Inhibitor)SASP-producing cells (Macrophages, T-cells)Inhibits JAK-STAT signaling, directly reducing IL−6/IL−12 and other SASP factorsJAK/STAT, NF-κBApprovedAdipose, Muscle, Hematopoietic systemMyelosuppression (anemia), infection risk; topical cream has higher safety281,330H-151Innate ImmunomodulatorcGAS-STING axis (Macrophages, Microglia)Blocks cGAS-STING signaling, inhibiting SASP-related NF-κB/IFN gene expressionInnate immunity, SASPPreclinicalBrain (Neurodegeneration), Kidney, AdiposeSuppression of anti-infective immunity; efficacy and safety need evaluation64CD153-CpG VaccineSenolytic (Vaccine)CD153+ senescent CD4 + T cellsInduces anti-CD153 antibodies, clearing senescent T cells in adipose via ADCC/CDCImmune clearance, Metabolic pathwaysPreclinicalAdipose tissue (Metabolic organs)Long-acting and stable effect; improves glucose tolerance291Anti-PD-1/PD-L1Immune Checkpoint BlockadePD − L1+ senescent cells (Widely distributed)Blocks PD-1/PD-L1 inhibitory signal, restoring CD8 + T-cell surveillance and clearancePD-1/PD-L1 pathwayApprovedLiver (NASH), Systemic immune systemRisk of immune-related adverse events (irAEs); p16-dependent regulation286TocilizumabAnti-IL-6R AntibodyIL-6 mediated inflammatory cellsNeutralizes IL-6 signaling, mitigating inflammagingIL-6 / STAT3ApprovedJoints, Systemic immune systemInfection risk; potential dyslipidemia and elevated liver enzymes335IL-7Cytokine TherapyNaive T cells, ThymusEnhances thymic hematopoiesis and naive T-cell output (thymic rejuvenation)IL-7R / JAK-STATPreclinical and ClinicalThymus, Lymphoid tissuePotential lymphoproliferative risk; mRNA delivery is an emerging trend281,336IL-2 (Low dose)Cytokine TherapyRegulatory T cells (Tregs)Selectively expands Tregs and improves activation capacity of senescent T cellsIL-2R / JAK-STATClinical Trials and Approved (High dose)Lymphoid system, ImmunomodulationHigh dose causes capillary leak; low dose is safe and promotes tolerance288TGF-β InhibitorAntibody / Small MoleculeImmune cells in tumor microenvironmentBlocks TGF-β to relieve immunosuppression; alleviates fibrosisTGF-β / SMAD, FibrosisEarly ClinicalTumor, Fibrotic tissues (Lung, Liver)Autoimmune risk; affects tissue homeostasis and repair337 Representative intervention strategies targeting immunosenescence Senolytics enabling selective elimination of senescent cells Senescent cells are characterized by expanded lysosomal content and elevated SA-β-gal activity. Exploiting this feature, the gemcitabine prodrug Senescence-Specific Killing compound 1 (SSK1) is selectively cleaved by SA-β-gal within senescent cells, releasing cytotoxic gemcitabine while sparing non-senescent cells with low basal SA-β-gal activity292. Targeting anti-apoptotic dependencies represents a well-established senolytic strategy. Many senescent cell states rely on BCL-2 family proteins for survival, rendering them susceptible to pharmacological inhibition. Navitoclax (ABT-263) and Venetoclax (ABT-199) disrupt BCL-2-mediated anti-apoptotic signaling275,293, facilitating mitochondrial apoptosis through Bax activation and promoting senescent cell clearance294. Recent advances employing nano-PROTAC conjugation have been developed to improve targeting specificity and reduce dose-limiting toxicities such as thrombocytopenia, enhancing the translational feasibility of these agents295. Senescent cells also experience heightened proteotoxic stress and display increased dependence on chaperone-mediated proteostasis. Inhibition of Heat Shock Protein 90 (HSP90) destabilizes client proteins essential for senescent cell survival, and HSP90 inhibitors such as geldanamycin derivatives preferentially induce senescent cell death in experimental systems284. Additional senolytic mechanisms target pro-survival signaling pathways. Dasatinib, a Src family kinase inhibitor, accelerates senescent cell clearance and exhibits enhanced efficacy when combined with quercetin, forming the widely studied D + Q cocktail296. Other flavonoids display senolytic or senomorphic activity through overlapping survival pathways. Fisetin interferes with PI3K-AKT-mTOR signaling while maintaining a favorable safety profile282, whereas rutin ameliorates endothelial dysfunction while promoting senescent cell clearance297. Emerging immunotherapeutic approaches harness immune recognition mechanisms to eliminate senescent cells. uPAR-CAR-T cells selectively recognize urokinase-type plasminogen activator receptor (uPAR) -expressing senescent cells and attenuate fibrosis in experimental liver and lung models298,299. In parallel, peptide vaccines targeting GPNMB stimulate endogenous antibody-mediated clearance of senescent vascular endothelial cells, highlighting the potential of immune-based senolysis289,300. Senescent cells also evade apoptosis through transcriptional sequestration of pro-apoptotic factors. FOXO4-DRI disrupts the FOXO4-p53 interaction, liberating p53 and triggering apoptosis selectively in senescent cells301. Similarly, cardiac glycosides such as ouabain and digoxin induce senolysis by inhibiting Na⁺/K⁺-ATPase, thereby disrupting ionic homeostasis and inducing apoptosis302. Senomorphics and immunometabolic reprogramming to restore immune function Rather than eliminating senescent cells, senomorphic strategies aim to attenuate SASP production and partially restore immune homeostasis. Central to this approach is modulation of nutrient-sensing and inflammatory pathways. Hyperactivation of mTOR is an important contributor to cellular senescence, and mTOR inhibitors such as rapamycin enhance autophagy303,304, support mitochondrial function, and reduce SASP-factor translation; these effects have been associated with improved immune-related readouts in experimental and selected clinical contexts305. Inflammatory transcriptional programs can also be modulated pharmacologically. Calcineurin inhibitors such as tacrolimus (FK506) suppress NF-AT nuclear translocation, limiting chronic T-cell activation and inflammatory cytokine transcription when administered at low doses306. AMPK activators, most notably metformin, antagonize mTOR signaling while inhibiting NF-κB-mediated inflammation, improving T-cell metabolic flexibility and selectively constraining pathogenic Th17 responses in relevant contexts307. Because SASP propagation relies in part on JAK/STAT signaling, JAK inhibitors such as ruxolitinib and tofacitinib inhibit JAK/STAT-dependent inflammatory signaling, but their use requires attention to infection risk and broader immune suppression284. Metabolic interventions further contribute to senomorphic effects. NAD⁺ supplementation supports sirtuin activity, mitochondrial oxidative phosphorylation, and DNA-repair pathways, with potential relevance to exhausted or metabolically constrained immune states308. Spermidine promotes autophagy and preserves mitochondrial protein translation in B cells, delaying age-associated humoral immune decline309. Mitochondria-targeted antioxidants, such as MitoQ and SkQ1, selectively accumulate within mitochondria to scavenge excess ROS and preserve mitochondrial architecture310. Finally, senescent cells exhibit increased reliance on glutaminolysis; GLS1 inhibitors such as BPTES and CB-839 exert dose-dependent effects, inducing senolysis at high concentrations while promoting metabolic reprogramming at lower doses243. Pleiotropic small-molecule modulators of immune aging Beyond canonical senotherapeutics, emerging evidence identifies pleiotropic small molecules that modulate immune aging via convergent, non-exclusive mechanisms. Rather than targeting isolated senescence nodes, these agents influence overlapping inflammatory, metabolic, redox, and stress-response pathways to shape systemic immune pathways. Conceptually, they occupy an intermediate niche between specific senolytics/senomorphics and lifestyle interventions, characterized by multi-target engagement and favorable safety profiles. Mechanistically, they converge on core signaling hubs, including NF-κB-mediated inflammation, mTOR-AMPK nutrient sensing, mitochondrial redox, and nucleic-acid sensing. Several archetypal compounds exemplify the biological diversity and evidence levels within this heterogeneous class. Polyphenols, notably resveratrol, suppress NF-κB-driven inflammation, enhance antioxidant defenses via catalase, and regulate autophagy/metabolism through AMPK/mTOR signaling311. Despite consistent preclinical efficacy, human outcomes vary, reflecting bioavailability and dosing disparities. A second subset comprises lipid-mediated modulators; cannabinoids, for instance, engage CB2, TRPV1, and PPARγ axes to influence inflammatory tone, oxidative stress, and DNA repair312. Their context-dependent effects, ranging from anti-inflammatory to immunosuppressive, underscore the critical role of dosage and immune baseline. Finally, compounds like ginkgolides target innate sensing by binding the STING adaptor, thereby attenuating cGAS-STING-mediated IFN-I responses313. While promising for mitigating nucleic-acid-driven inflammaging, human translational evidence remains limited. Importantly, these examples do not represent isolated cases but rather illustrative nodes within a much larger pharmacological landscape of small molecules with documented effects on immune aging-relevant pathways. Numerous additional compounds, including flavonoids, terpenoids, alkaloids, and microbiota-derived metabolites, have been shown to modulate immune cell metabolism, redox balance, or inflammatory signaling in preclinical models314,315 (Table 3). For clarity and rigor, this review focuses on representative agents with relatively well-characterized mechanisms and reproducible experimental evidence. Table 3Representative small-molecule modulators of immunosenescenceNatural compoundClassificationSourcePrimary targetsKey anti-aging mechanismRef.SalidrosideGlycosideRhodiola rosea (Root)HSP90, Nrf2Inhibits HSP90 ATPase activity; activates Nrf2 to reduce ROS and extend lifespan314ThymoquinoneTerpenoidNigella sativa (Seeds)SIRT1, TERTActivates SIRT1/FOXO3a axis to upregulate telomerase TERT and protect organs315Urolithin AMicrobial MetabolitePomegranate ellagitanninsMitophagy, TSCMInduces PINK1/Parkin mitophagy; expands memory stem-like T cells in humans338SpermidineAlkaloidWheat germ, SoybeansEIF5A, TFEBPromotes EIF5A hypusination to enhance TFEB translation and maintain autophagy339BerberineAlkaloidCoptis chinensis (Rhizome)AMPK, p16Optimizes energy sensing; regulates p16 to extend model organisms’ lifespan340Astragaloside IVTerpenoidAstragalus (Root)FTO, m6A, IL-1βTargets FTO to reduce IL-1βmRNA stability and delay epithelial senescence341CurcuminPolyphenolCurcuma longa (Rhizome)IRE1, miR-1249Suppresses IRE1/JNK/CASPASE3 pathway to alleviate ER stress and apoptosis342EGCGPolyphenolGreen tea (Leaves)OMA1, Nrf2Binds OMA1 to protect mitochondrial cristae; activates Keap1/Nrf2 cascade343CelastrolTerpenoidT. wilfordii (Root bark)TXNRD1, NLRP3Upregulates TXNRD1 to induce NLRP3 ubiquitination and degradation343HonokiolPolyphenolMagnolia (Bark)Ucp3, SIRT3Ucp3, SIRT3 Activates SIRT3 to upregulate Ucp3, regulating proton leak and decreasing ROS344FucoxanthinTerpenoidBrown Algae (Leaves)PI3K/Akt, p16PI3K/Akt, p16 Regulates brain transcriptome and reduces p16/p21 markers in systemic organs345PterostilbenePolyphenolBlueberries, GrapesPDE4A, BDNFInhibits PDE4A to activate CREB-BDNF path; improves mitochondrial quality346Ginsenoside Rg1TerpenoidPanax ginseng (Root)Notch, VEGFRemodels stem cell niches via Notch; enhances immune repair resilience347 Representative small-molecule modulators of immunosenescence Collectively, pleiotropic small molecules offer a complementary strategy for modulating immunosenescence, particularly when wholesale senescent-cell elimination is undesirable. However, clinical translation remains constrained by heterogeneous human data and context-dependent effects. These agents are best viewed as modulators of immune aging trajectories, rather than definitive senescence-reversing therapies, necessitating integration with biomarker-guided stratification in future studies. Contextual and environmental interventions System-level interventions complement pharmacology by targeting the physiological context of immune aging. Contextual and environmental interventions broadly refer to modifiable microbial, dietary, behavioral, and physical-environmental inputs that may shape immune-aging trajectories by acting on microbial ecology, immunometabolism, tissue niches, barrier integrity, and inflammatory tone316. Examples include microbiota modulation, caloric restriction, intermittent fasting, exercise, and hyperbaric oxygen therapy. Caloric restriction (CR) and intermittent fasting (IF) modulate nutrient-sensing via mTORC1/IGF-1 inhibition, restoring HSC regenerative capacity, correcting myeloid bias, and alleviating metabolic stress317. CR additionally suppresses PLA2G7, mitigating thymic lipotoxicity and systemic oxidative stress318. Exercise, a potent physiological modulator, releases myokines, such as IL-15 and IL-6, which enhance thymic naïve T-cell output and NK-cell cytotoxicity. Rather than functioning as a direct senolytic therapy, exercise is better interpreted as a systemic immunometabolic intervention that supports immune surveillance, tissue repair, and senescent-cell turnover319. Young-donor fecal microbiota transplantation has been reported to improve microbial composition and attenuate neuroinflammatory phenotypes in experimental models, with effects on cognitive readouts211. Hyperbaric oxygen therapy has been associated with angiogenic responses, changes in T-cell telomere length, and tissue-repair readouts, although durability and generalizability require further evaluation320. These interventions require attention to dose, timing, baseline immune status, tissue context, and potential trade-offs, including impaired wound healing, infection risk, impaired vaccine responses, unintended immune suppression, and reduced tumor surveillance. Clinical evidence, longitudinal immune-resilience markers, and translational limitations Clinical evidence for interventions targeting immunosenescence remains heterogeneous and, as reflected in the levels of evidence detailed in Table 2, is often limited by small sample sizes, short follow-up, disease-specific cohorts, and biomarker-focused endpoints. Direct evidence that these interventions durably reverse immunosenescence or improve multi-organ aging trajectories in humans remains limited. Moreover, immune aging is heterogeneous across sex, tissue context, baseline inflammatory tone, infection history, comorbidities, and medication exposure. These sources of heterogeneity complicate the interpretation of therapeutic response and emphasize the need for stratified trial designs. Several longitudinal or large-scale clinical studies have begun to capture selected dimensions of immune resilience and biological aging, including immune-age metrics, vaccine-response-associated immune profiling, phenotypic aging trajectories, and frailty-related proteomic signatures321–323. For example, IMM-AGE supports the feasibility of longitudinal immune-age modeling101, while large-scale plasma proteomic analyzes of frailty have identified proteomic frailty scores associated with incident disease risk and age-related frailty progression322. However, no single longitudinal aging framework has yet integrated the full spectrum of immune-resilience markers relevant to immunosenescence, including vaccine responsiveness, infection incidence and recovery, TCR/BCR repertoire diversity, naïve/memory T-cell balance, CD4/CD8 ratio, T-cell senescence markers such as p16INK4a, SASP/inflammatory proteomic panels, epigenetic immune age, single-cell immune atlases, frailty trajectories, and multimorbidity progression322,324,325. Future studies should therefore combine functional immune outcomes, inflammatory and senescence-associated biomarkers, and organ-level aging trajectories to determine whether immune resilience acts as a predictor, mediator, or modifiable component of healthy aging324. Overall, current evidence is strongest for mechanistic plausibility and biomarker modulation in preclinical models or early clinical settings, whereas durable improvement in immune-aging phenotypes and organ-level outcomes remains to be established through adequately powered longitudinal clinical studies101,321,322. Perspectives and conclusion Several unresolved controversies remain central to the interpretation of immunosenescence. First, current evidence does not support a single causal direction between inflammaging and immune aging. In some contexts, chronic inflammatory environments appear to reshape immune-cell differentiation, exhaustion, and senescent conversion, whereas in others, senescent or chronically activated immune cells can amplify local or systemic inflammatory tone. Thus, inflammaging is best interpreted as both a potential driver and consequence of immunosenescence, depending on tissue context and disease stage. Second, senescent or senescence-like immune states are not uniformly detrimental. Although persistent senescent immune programs can sustain SASP-associated inflammation, fibrosis, and impaired immune surveillance, transient senescence-like responses may limit excessive proliferation, support wound repair, contribute to infection containment, and participate in tumor-suppressive programs. Therefore, immunosenescence should not be framed as purely pathological. From an adaptive or evolutionary perspective, age-associated immune remodeling may reflect trade-offs among antimicrobial defense, inflammatory restraint, tissue repair, and cancer suppression, becoming maladaptive when these programs persist, spread across tissues, or occur in hosts with reduced regenerative reserve. Despite substantial progress, causal inference remains limited. Immune aging is heterogeneous across cell types, tissues, individuals, sex, infection history, and disease states, and current models do not fully distinguish adaptive remodeling, activation, exhaustion, and maladaptive senescent conversion. Candidate contributors, such as clonal hematopoiesis, lifelong antigenic stimulation, immunometabolic remodeling, and biophysical niche changes, often operate in coupled feedback circuits. Immunometabolism should therefore be framed as an important emerging mechanistic axis rather than a fully established central determinant of aging. Clarifying causal direction will require longitudinal clinical studies, tissue-resolved immune profiling, perturbation-based experimental systems, and, where appropriate, genetic, transplantation, or senescent-cell clearance models. Translationally, these uncertainties argue against a single indiscriminate “anti-senescence” strategy. Senotherapeutic and senomorphic approaches should be matched to cell state, tissue context, disease stage, and immune function. Key challenges include target specificity, off-target toxicity, myelosuppression, impaired antimicrobial defense, altered vaccine responsiveness, defective tissue repair, and reduced tumor surveillance. Future studies should integrate senescent-cell burden, immune-cell composition, inflammatory and proteomic biomarkers, immune-repertoire diversity, vaccine responsiveness, infection outcomes, frailty trajectories, and multimorbidity progression. Together, these efforts may move the field from descriptive immune-aging signatures toward mechanism-informed interventions that can be tested for their ability to safely modulate immune resilience and organ-specific aging outcomes. Immunosenescence is increasingly recognized as a systemic and context-dependent component of organismal aging rather than a simple decline in antimicrobial defense. Across innate and adaptive immune compartments, age-associated immune remodeling is commonly associated with altered basal inflammatory tone, reduced response fidelity, changes in tissue-repair programs, and weakened immune surveillance in selected contexts. Through soluble mediators, nucleic-acid danger signals, extracellular vesicles, altered immune-cell trafficking, and impaired clearance mechanisms, immune aging can become linked to organ-level dysfunction. However, these relationships should not be interpreted as uniformly causal or unidirectional, because aging tissues can also reshape immune niches through endocrine, metabolic, neural, microbial, vascular, stromal, and damage-associated feedback signals. Overall, immunosenescence is best understood as a context-dependent driver, amplifier, and consequence of tissue aging, with its biological impact determined by cell state, tissue environment, disease stage, and host resilience. Acknowledgements This work was supported by a grant from the National Key Research and Development Program of China (2025YFC3507902), The National Science Foundation of China (82374406 and 82505436), the Guangdong Provincial Natural Science Foundation (2026A1515012409), the Guangdong Special Support Program for Health Talents (0920260), Guangdong Basic and Applied Basic Research Foundation (2023A1515030146), Guangzhou University of Chinese Medicine’s Youth Elite Talents Cultivation “List Unveiling and Leading” Team Project, 2023 Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital Young and Middle-aged Backbone Talent Cultivation Project, The Funding Project of the Guangdong Provincial Department of Education (2024KTSCX114), Guangzhou Science and Technology Plan Project (2025A04J5311), and Guangdong Provincial Administration of Traditional Chinese Medicine (20264102). Author contributions Z.-G.W.: Investigation, Visualization, Writing – original draft. Q.-Q.Z., S.-R.L., J.-Y.L., and C.-J.Y.: Investigation, Validation, Visualization. S.-N.S., Z.-Q.Y., S.-H.N.: Supervision, Funding acquisition, Writing – review & editing. X.-L.C. and L.L.: Conceptualization, Supervision, Funding acquisition, Writing – review & editing. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Shu-Ning Sun, Email: 28191109201@stu.gzucm.edu.cn. Zhong-Qi Yang, Email: yang_zhongqi@163.com. Shi-Hao Ni, Email: Shihao_Ni@163.com. Xing-Ling Chen, Email: chenxingling0218@163.com. Lu Lu, Email: coinland@gzucm.edu.cn. References